Substance P markedly ameliorates scopolamine-induced impairment of spontaneous alternation performance in the mouse

Brain Res. 1995 Mar 6;673(2):335-8. doi: 10.1016/0006-8993(94)01460-y.

Abstract

We investigated the effects of intracerebroventricular injection of substance P (SP) on the scopolamine (1 mg/kg)-induced impairment of spontaneous alternation performance in the mouse. SP (0.001-3 micrograms) alone did not influence either spontaneous alternation performance or total arm entries. Scopolamine (1 mg/kg) impaired spontaneous alternation performance accompanied by an increment in total arm entries. In contrast, SP (0.01-1 micrograms) significantly improved the scopolamine (1 mg/kg)-induced impairment of spontaneous alternation performance without influencing the scopolamine (1 mg/kg)-induced increase in total arm entries. The effects of SP (0.1 micrograms) on the scopolamine (1 mg/kg)-induced impairment of spontaneous alternation performance were almost completely reversed by pretreatment with WIN 62577 (1 mg/kg), a tachykinin NK-1 receptor antagonist. These results suggest that SP improves the scopolamine-induced impairment of spontaneous alternation performance through the mediation of tachykinin NK-1 receptors.

MeSH terms

  • Androstenes / pharmacology
  • Animals
  • Benzimidazoles / pharmacology
  • Dose-Response Relationship, Drug
  • Learning Disabilities*
  • Male
  • Mice
  • Neurokinin-1 Receptor Antagonists
  • Scopolamine / pharmacology
  • Substance P / pharmacology*

Substances

  • Androstenes
  • Benzimidazoles
  • Neurokinin-1 Receptor Antagonists
  • WIN 62577
  • Substance P
  • Scopolamine